Filter by:
Muscular Dystrophy
March 2025
2025 MDA Annual Clinical and Scientific Conference
CANYON trial results: Sevasemten, an investigational fast skeletal myosin inhibitor, reduced muscle damage biomarkers and stabilized function in Becker muscular dystrophy (BMD)
Muscular Dystrophy
March 2025
Symposium at the 2025 MDA Annual Clinical and Scientific Conference
Spotlight on Becker Muscular Dystrophy: Understanding the Lived Experience of Becker and Clinical Advancements with a Novel Agent
Muscular Dystrophy
March 2025
2025 MDA Annual Clinical and Scientific Conference
The Skeletal Phenotype in Becker Muscular Dystrophy: The Under-Studied Cousin of Duchenne
Muscular Dystrophy
March 2025
2025 MDA Annual Clinical and Scientific Conference
Two-year Sevasemten Treatment Outcomes in Becker Muscular Dystrophy Compared to Natural History Controls for the North Star Ambulatory Assessment
Muscular Dystrophy
March 2025
2025 MDA Annual Clinical and Scientific Conference
Myosin inhibitor EDG-4131 improves pathophysiology and molecular pathology in BMD model mice
Muscular Dystrophy
March 2025
2025 MDA Annual Clinical and Scientific Conference
